9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study.

          Related collections

          Author and article information

          Journal
          Eur. J. Cancer
          European journal of cancer (Oxford, England : 1990)
          Elsevier BV
          1879-0852
          0959-8049
          September 2017
          : 83
          Affiliations
          [1 ] Universitätsmedizin Charité Berlin, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany. Electronic address: philipp.lohneis@charite.de.
          [2 ] Universitätsmedizin Charité Berlin, CONKO Study Group, Department of Medical Oncology, Haematology and Tumorimmunology, Augustenburger Platz 1, 13353 Berlin, Germany.
          [3 ] Universitätsmedizin Charité Berlin, Department of General, Visceral and Transplantation Surgery, Augustenburger Platz 1, 13353 Berlin, Germany.
          [4 ] Universitätsmedizin Charité Berlin, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany.
          [5 ] Outpatient Department Hematology/Oncology, Friedrichstrasse 53, 88045 Friedrichshafen, Germany.
          Article
          S0959-8049(17)31067-5
          10.1016/j.ejca.2017.06.016
          28772128
          66aee2ea-fd81-4125-8a6f-d83fa67ba13f
          History

          Tumour-infiltrating lymphocytes,CD3,CD8,Gemcitabine,Pancreatic cancer,T lymphocytes,CD103

          Comments

          Comment on this article